Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Auxotrophic vaccines for tuberculosis

Nature Medicine volume 2, pages 334–337 (1996)Cite this article

Abstract

Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually1. It remains the largest attributable cause of death in HIV–infected individuals, responsible for 32% of deaths of HIV–infected individuals in Africa2. The only currently available vaccine for tuberculosis, bacille Calmette–Guerin (BCG) is the most widely used vaccine in the world, being administered to approximately 100 million children each year. Although untoward effects were not seen in several studies of HIV–seropositive children3, the safety of live attenuated BCG vaccine in HIV–positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCG produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCG could no longer be detected in mice receiving the auxotrophs after 16–32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCG vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged with virulent Mycobacterium tuberculosis, several of the auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCG. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Murray, C.J.L. & Lopez, A.D. Global Comparative Assessments in the Health Sector: Disease Burden, Expenditures and Intervention Packages (eds. Murray, C.J.L. & Lopez, A.D.) 53 (World Health Organization, Geneva, 1994).

    Google Scholar 

  2. Lucas, S. & Nelson, A.M. Pathogenesis of tuberculosis in human immunodeficiency virus infected people. in Tuberculosis, Pathogenesis, Protection and Control (ed. Bloom, B.R.) 503–513 (American Society for Microbiology Press, Washington, DC, 1994).

    Google Scholar 

  3. Program for Immunization. Program Report (World Health Organization, Geneva, 1992).

  4. Styblo, K. Epidemiology of tuberculosis. Selected Papers R. Netherlands Tuberc. Assoc. 24, 1–136 (1991).

    Google Scholar 

  5. Selwyn, P.A. et al. A prospective study of the risk of tuberculosis among intravenous drug abusers with human immunodeficiency virus infection. N. Engl. J. Med. 320, 545–550 (1989).

    Article  CAS  Google Scholar 

  6. Rodrigues, L.C., Diwan, V.K. & Wheeler, J.G. Protective efficacy of BCG against tuberculousmeningitisandmiliary tuberculosis: Meta-analysis. Int. J. Epidemiol. 22, 1154–1158 (1993).

    Article  CAS  Google Scholar 

  7. Fine, P.E.M. The BCG story: Lessons from the past and implications for the future. Rev. Infect. Dis. 11, S353–S359 (1989).

    Article  Google Scholar 

  8. tenDam, H.G., Toman, K.I., Hitze, K.L., & Guld, J., Present knowledge of immunization against tuberculosis. Bull World Health Organ. 54, 255–269 (1976).

    Google Scholar 

  9. Hart, P.D. & Sutherland, I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 22, 293–295 (1977).

    Article  Google Scholar 

  10. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J. Med. Res. 72, 1–74 (1980).

  11. Bloom, B.R. & Fine, P.E.M. The BCG Experience: Implications for future vaccines against tuberculosis, in Tuberculosis, Pathogenesis, Protection and Control (ed. Bloom, B.R.) 531–557 (American Society for Microbiology Press, Washington, DC, 1994).

    Google Scholar 

  12. Colditz, G.A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of published literature [see comments] (1994). Comments in: ACP J. Club 121 (Jul-Aug), Suppl. 1, 22 (1994); Comment in: JAMA 272, 765 (1994); Discussion 766.

    Google Scholar 

  13. vonReyn, C.F. et al. Human immunodeficiency virus infection and routine childhood immunization. Lancet ii, 669–672 (1987).

    Article  Google Scholar 

  14. Braun, M.M. & Cauthen, G. Relationship of the human deficiency virus epidemic to paediatric tuberculosis and bacillus Calmette-Guerin immunization. Pediatr. Infect. Dis. J. 11, 220–227 (1992).

    Article  CAS  Google Scholar 

  15. Weltman, A.C. & Rose, D.N. The safety of bacille Calmette-Guerin vaccination in HIV infection and AIDS. AIDS 7, 149–157 (1993).

    Article  CAS  Google Scholar 

  16. Germanier, R. & Furer, E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131, 553–558 (1975).

    Article  CAS  Google Scholar 

  17. Curtiss, R. III, & Kelly, S.M., Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55, 3035–3043 (1987).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Hoiseth, S. & Stocker, B.A.D. Aromatic dependent Salmonella typhimurium are non-virulent and are effective as live vaccines. Nature 291, 238–239 (1981).

    Article  CAS  Google Scholar 

  19. Dougan, G. et al. Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes. J. Infect. Dis. 158, 1329 (1988).

    Article  CAS  Google Scholar 

  20. Miller, I.A. et al. Bacteriophage P22 as a vehicle for transducing cosmid gene banks between smooth strains of Salmonella typhimurium: Use in identifying a role for aroD in attenuating virulent Salmonella strains. Mol. Gen. Genet. 215, 312–316 (1989).

    Article  CAS  Google Scholar 

  21. Wahdan, M.H., Serie, C., Cerisier, Y., Sallam, S. & Germanier, R. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three-year results. J. Infect. Dis. 145, 292–295 (1982).

    Article  CAS  Google Scholar 

  22. McAdam, R.A. et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis-BCG generated by transposon mutagenesis. Infect. Immun. 63, 1004–1012 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Ganjam, K., Bloom, B.R. & Jacobs, W.R., Jr. Insertional mutagenesis and illegitimate recombination in mycobacteria. Proc. Natl. Acad. Sci. USA 88, 5433–5443 (1991).

    Article  Google Scholar 

  24. North, R.J. & Izzo, A.A. Mycobacterial virulence: Virulent strains of Mycobacterium tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J. Exp. Med. 177, 1723–1733 (1993).

    Article  CAS  Google Scholar 

  25. Orme, I.M. and Collins, F.M. Mouse model of tuberculosis, in Tuberculosis, Pathogenesis, Protection and Control (ed. Bloom, B.R.) 113–134 (American Society for Microbiology Press, Washington, DC, 1994).

  26. Cooper, A.M. et al. Disseminated tuberculosis in IFN-γ gene-disrupted mice. J. Exp. Med. 178, 2242–2248 (1993).

    Article  Google Scholar 

  27. Flynn, J.L. et al. An essential role for IFN-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249–2254 (1993).

    Article  CAS  Google Scholar 

  28. Flynn, J.L., Goldstein, M.M., Triebold, K.J., Koller, B. & Bloom, B.R. Major histocompatibility class I-restricted T-cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89, 12013–12017 (1992).

    Article  CAS  Google Scholar 

  29. Flynn, J.L. et al. Tumor necrosis factor a is required in the protective immune response against M. tuberculosis in mice. Immunity 2, 561–572, 1995.

    Article  CAS  Google Scholar 

  30. Cooper, A.M. et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84, 423–432 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Flynn, J.L., Goldstein, M.M., Triebold, K.J., Wolf, S. & Bloom, B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155, 2515–2524 (1995).

    CAS  PubMed  Google Scholar 

  32. Stover, C.K. et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine. J. Exp. Med. 178, 197–209 (1993).

    Article  CAS  Google Scholar 

  33. Connell, N.D., Medina-Acosta, E., McMaster, W.R., Bloom, B.R. & Russell, D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 90, 11473–11477 (1993).

    Article  CAS  Google Scholar 

  34. Fennelly, G.J., Flynn, J.L., terMeulen, V., Liebert, U., & Bloom, B.R., Recombinant bacille Calmette-Guerin (BCG) (rBCG) priming against measles. J. Infect. Dis. 172, 698–705 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Howard Hughes Medical Institute, and Department of Microbiology, and Immunology, Albert Einstein College of Medicine, Bronx, New York, 10461, USA

    Indira Guleria, Rachel Teitelbaum, Ruth A. McAdam, Ganjam Kalpana, William R. Jacobs Jr & Barry R. Bloom

Authors
  1. Indira Guleria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Teitelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth A. McAdam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ganjam Kalpana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William R. Jacobs Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barry R. Bloom
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guleria, I., Teitelbaum, R., McAdam, R. et al. Auxotrophic vaccines for tuberculosis. Nat Med 2, 334–337 (1996). https://doi.org/10.1038/nm0396-334

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0396-334

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing